营业成本增速高于营业收入增速遭问询 健麾信息回复

Group 1 - The core issue highlighted is that the company's total operating costs have been growing at a rate significantly higher than its operating revenue, attracting the attention of the stock exchange [1][2] - In 2024, the company's operating revenue increased by 3.51% to 318 million yuan, while total operating costs surged by 33.48% to 292 million yuan [1] - For the first half of 2025, operating revenue rose by 9.03% to 159 million yuan, but total operating costs also increased by 33.18% to 140 million yuan [1] Group 2 - The decline in revenue from the traditional core business, the smart pharmacy project, was a significant factor, with a 56.84% drop to 86.39 million yuan and a corresponding decrease in gross margin by 12.83 percentage points [1] - New emerging businesses, such as the intelligent centralized dispensing center, experienced explosive growth with a revenue increase of 675.85% to 119 million yuan, but the high costs reduced overall profitability, with a gross margin of only 29.55%, down 16.86 percentage points from the previous year [1] - In the first half of 2025, the cost pressures from emerging businesses became more pronounced, with the intelligent centralized dispensing center's revenue increasing by 159.77%, but the newly added digital operating room module project had a gross margin of only around 20%, approximately 40 percentage points lower than the existing intravenous medication preparation system [2]